Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.3B
309M shares
52-week range
$2.23 – $6.51
45% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.39%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27.9M | $63.0M | $65.1M | $75.4M | $99.8M | $199.0M | $285.5M | $349.0M |
| Cost of revenue | $20.5M | $28.0M | $24.6M | $38.9M | $57.5M | $62.8M | $76.6M | $61.2M |
| Gross profit | $7.4M | $35.1M | $40.5M | $36.6M | $42.3M | $136.2M | $208.9M | $287.8M |
| Gross margin | 26.5% | 55.6% | 62.2% | 48.5% | 42.4% | 68.5% | 73.2% | 82.5% |
| R&D | $8.7M | $6.9M | $6.2M | $12.3M | $19.7M | $31.3M | $45.9M | $66.3M |
| Operating income | −$76.6M | −$44.6M | −$47.9M | −$47.0M | −$64.1M | $8.7M | $72.6M | $38.8M |
| EBITDA | −$75.6M | −$38.8M | −$44.7M | −$61.1M | −$56.3M | $15.1M | $77.5M | $27.5M |
| Net income | −$87.0M | −$51.9M | −$57.2M | −$80.9M | −$87.4M | −$11.9M | $27.6M | $5.9M |
| Net margin | -312.2% | -82.3% | -87.9% | -107.3% | -87.6% | -6.0% | 9.7% | 1.7% |
| EPS (diluted) | -0.60 | -0.31 | -0.26 | -0.37 | -0.44 | -0.04 | 0.10 | 0.02 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $462M | $-0.02 | $-0.05–$0.02 | 5 |
| 2027 | $521M | $0.14 | $0.05–$0.31 | 5 |
| 2028 | $536M | $0.16 | $-0.24–$0.38 | 8 |
| 2029 | $611M | $0.31 | $0.29–$0.33 | 6 |
Forward consensus · source: Financial Modeling Prep
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
www.mannkindcorp.comNo one on the platform currently holds MNKD.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,868,442 | $4.6M |
| Execution date | Ratio |
|---|---|
| 2017-03-03 | 1-for-5reverse |
No one on the platform has traded MNKD yet.
| $2.4B |
| — |
| HRMYHarmony Biosciences Holdings, Inc. | $34.93 | -1.52% | $2.0B | — |
| IMCRImmunocore Holdings plc | $30.58 | -0.98% | $1.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
whenever the spreads have widened out to more than their usual penny on a regular basis, it has historically meant that "big fish" are swimming in the waters (i.e. the market makers have sizable orders they are working for clients), and, in most (but not all!) cases, the daily "clue" has often preceded nice moves to the upside for $MNKD once "enough" stock has been accumulated at the lower prices (and, as you've probably noticed, this phenomenon clearly seems to be playing out this time around as well). I hope that helps... and, of course, stay tuned, eh? ;-)
View on StockTwits ↗$MNKD Mannkind has completed the Cohort 1 phase of the MNKD-201 study showing positive results and just needs to complete Cohort 2 phase that I expect is already done. Top line results will hopefully be out in early July. https://clinicaltrials.gov/study/NCT07344558?term=mannkind&viewType=Card&aggFilters=status:rec&rank=1 Experimental: Cohort 1: MNKD-201 Target Dose or placebo Participants will receive a target dose of MNKD-201 (Nintedanib DPI) or placebo, administered via oral inhalation three times daily for 7 days Experimental: Cohort 2: MNKD-201 High Dose or placebo Participants will receive a high dose of MNKD-201 (Nintedanib DPI) or placebo, administered via oral inhalation twice daily for 7 days Study Start (Actual) 2025-12-22 Primary Completion (Estimated) 2026-06-15 Study Completion (Estimated) 2026-06-15 Enrollment (Estimated) 24 https://investors.mannkindcorp.com/static-files/0fe6a91e-b0f6-4794-812a-38bec1620bac
View on StockTwits ↗$MNKD here's what's not huge : the avg. new scripts per sales, general and administrative employee for week ending 6 19 is 0.996 scripts... less than 1 new one per employee...lol
View on StockTwits ↗$MNKD Just one more day and 3Q 2026, begins. Mannkind has stated they will release results from the MNKD-201 Phase IB Study in the 3Q 2026 and Clinicaltrials.gov website has a primary completion and study completion dates for the study for 6/15/2026 and the website was last updated on 5/5/2026. I hope and expect results from the study should not take long to determine and Mannkind should have them ready to release in early July. Positive results from the study and the FDA allowing MNKD-201 to add locations to enroll patients in the United States and allow approval in the United States will be huge.
View on StockTwits ↗$MNKD This should be at, at least, $5 but nope. Weak management, weak pipeline, and weak sales explain why this is still a penny stock.
View on StockTwits ↗$MNKD is it a fact that afrezza dpi inhaled prandial insulin approved in 2014 is the only insulin in the world with the FDA black box warning label...ouch ...
View on StockTwits ↗$MNKD Mannkind stock, nice trend and continuation breakout at https://stockconsultant.com/?MNKD
View on StockTwits ↗$MNKD Is this true that if Mannkind finds a new CEO that the company will be
View on StockTwits ↗$MNKD Is today going to be the typical Mannkind Monday where stockholders
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Trading at 3.8× sales vs its 5.8× historical median P/S.
Fair value ≈ $6.33 · price $4.13 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.